<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858520</url>
  </required_header>
  <id_info>
    <org_study_id>B32220072389</org_study_id>
    <secondary_id>S50623</secondary_id>
    <nct_id>NCT00858520</nct_id>
  </id_info>
  <brief_title>Serum, Plasma, DNA and Tissue Bank in Chronic Obstructive Pulmonary Disease and Lung Cancer</brief_title>
  <official_title>Serum, Plasma, DNA and Tissue Bank of Patients With Chronic Obstructive Pulmonary Disease, Lung Cancer and Smoking Controls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A biobank of Serum, plasma, DNA samples together with clinical information including specific&#xD;
      questionnaires, complete pulmonary function and chest CT-scan, is prospectively collected in&#xD;
      patients seen at the investigators' clinical service.&#xD;
&#xD;
      The objective is to study candidate gene pathways in COPD and or lung cancer and to associate&#xD;
      them with the clinical characteristics and phenotypes of COPD/emphysema and lung cancer.&#xD;
&#xD;
      In subgroups of well characterised patients, other biological materials are also collected&#xD;
      (lung tissue biopsies, peripheral blood mononuclear cells).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with a smoking history of at least 15 pack years, an minimal age of 50 years and&#xD;
      an recent available CT scan are enrolled.&#xD;
&#xD;
      All subjects with a diagnosis of lung cancer are also collected (irrespective of age and&#xD;
      smoking behavior).&#xD;
&#xD;
      In addition the investigators collect:&#xD;
&#xD;
        -  specific questionnaires (MRC, CCQ and smoking history)&#xD;
&#xD;
        -  medical and professional history&#xD;
&#xD;
        -  complete pulmonary function (spirometry, bodyplethysmography and diffusing capacity)&#xD;
&#xD;
        -  serum, plasma and DNA samples.&#xD;
&#xD;
      In specific subgroups the investigators also collect:&#xD;
&#xD;
        -  Peripheral blood mononuclear cells&#xD;
&#xD;
        -  Lung tissue - if available - from a surgical procedure (lung transplantation or&#xD;
           lobectomy)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serological, cytological, histological and genetic analysis of biomarkers or genes which are involved in the pathogenesis of COPD/Emphysema/Lungcancer.</measure>
    <time_frame>0-1-3-6 years</time_frame>
    <description>All cases are prospectively collected in University hospital Leuven, Belgium. Of enrolled subjects data are collected at 0,1,3 and 6 years interval</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Smoking controls</arm_group_label>
    <description>Smokers without lung cancer and without COPD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <description>Smokers with COPD but without lung cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung cancer patients</arm_group_label>
    <description>smokers - never smokers with lung cancer</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Germline DNA, serum and plasma, Peripheral blood mononuclear cells, Lung tissue biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Chronic Obstructive Pulmonary Disease and smoking controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for smokers:&#xD;
&#xD;
          -  A smoking history of at least 15 pack years and age of 50 years or older&#xD;
&#xD;
          -  Complete pulmonary function on day of visit&#xD;
&#xD;
          -  Chest CT-scan within one year of enrollment&#xD;
&#xD;
          -  4 weeks from exacerbation&#xD;
&#xD;
        Exclusion Criteria for smokers:&#xD;
&#xD;
          -  Less than 15 pack years&#xD;
&#xD;
          -  Younger than 50 year&#xD;
&#xD;
          -  Other pulmonary diseases interfering with CT or pulmonary function&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
        Inclusion Criteria for lung cancer patients:&#xD;
&#xD;
          -  new diagnosis of proven lung cancer&#xD;
&#xD;
          -  chest CT scan within 2 months of enrollment&#xD;
&#xD;
          -  Complete pulmonary function&#xD;
&#xD;
        Exclusion Criteria for lung cancer patients&#xD;
&#xD;
          -  not able to perform pulmonary function&#xD;
&#xD;
          -  Absence of histological diagnosis of lung cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Janssens, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wim Janssens, MD. PhD.</last_name>
    <phone>032 (16) 34 68 00</phone>
    <email>wim.janssens@uz.kuleuven.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristien Debent</last_name>
    <phone>032 (16) 34 31 26</phone>
    <email>kristien.debent@uz.kuleuven.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flanders</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wim Janssens, Prof</last_name>
      <phone>032 (16) 34 68 00</phone>
      <email>wim.janssens@uz.kuleuven.ac.be</email>
    </contact>
    <investigator>
      <last_name>Wim Janssens, MD. PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Decramer, MD. PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diether Lambrechts, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johan Vansteenkiste, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Deleyn, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <last_update_submitted>September 2, 2013</last_update_submitted>
  <last_update_submitted_qc>September 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Marc Decramer</investigator_full_name>
    <investigator_title>Prof.Dr.</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>genes</keyword>
  <keyword>DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

